540 related articles for article (PubMed ID: 14612542)
1. Differential induction of topoisomerase I-DNA cleavage complexes by the indenoisoquinoline MJ-III-65 (NSC 706744) and camptothecin: base sequence analysis and activity against camptothecin-resistant topoisomerases I.
Antony S; Jayaraman M; Laco G; Kohlhagen G; Kohn KW; Cushman M; Pommier Y
Cancer Res; 2003 Nov; 63(21):7428-35. PubMed ID: 14612542
[TBL] [Abstract][Full Text] [Related]
2. Cellular topoisomerase I inhibition and antiproliferative activity by MJ-III-65 (NSC 706744), an indenoisoquinoline topoisomerase I poison.
Antony S; Kohlhagen G; Agama K; Jayaraman M; Cao S; Durrani FA; Rustum YM; Cushman M; Pommier Y
Mol Pharmacol; 2005 Feb; 67(2):523-30. PubMed ID: 15531731
[TBL] [Abstract][Full Text] [Related]
3. Molecular modeling studies of the DNA-topoisomerase I ternary cleavable complex with camptothecin.
Fan Y; Weinstein JN; Kohn KW; Shi LM; Pommier Y
J Med Chem; 1998 Jun; 41(13):2216-26. PubMed ID: 9632354
[TBL] [Abstract][Full Text] [Related]
4. Characterization of a novel topoisomerase I mutation from a camptothecin-resistant human prostate cancer cell line.
Urasaki Y; Laco GS; Pourquier P; Takebayashi Y; Kohlhagen G; Gioffre C; Zhang H; Chatterjee D; Pantazis P; Pommier Y
Cancer Res; 2001 Mar; 61(5):1964-9. PubMed ID: 11280753
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of resistance to topoisomerase I-targeting drugs.
Rasheed ZA; Rubin EH
Oncogene; 2003 Oct; 22(47):7296-304. PubMed ID: 14576839
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and biological evaluation of cytotoxic 11-alkenylindenoisoquinoline topoisomerase I inhibitors and indenoisoquinoline-camptothecin hybrids.
Fox BM; Xiao X; Antony S; Kohlhagen G; Pommier Y; Staker BL; Stewart L; Cushman M
J Med Chem; 2003 Jul; 46(15):3275-82. PubMed ID: 12852757
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of camptothecin-induced topoisomerase I cleavage complexes by the acetaldehyde adduct N2-ethyl-2'-deoxyguanosine.
Antony S; Theruvathu JA; Brooks PJ; Lesher DT; Redinbo M; Pommier Y
Nucleic Acids Res; 2004; 32(18):5685-92. PubMed ID: 15498925
[TBL] [Abstract][Full Text] [Related]
8. Persistence of camptothecin analog-topoisomerase I-DNA ternary complexes: a molecular dynamics study.
Siu FM; Che CM
J Am Chem Soc; 2008 Dec; 130(52):17928-37. PubMed ID: 19035632
[TBL] [Abstract][Full Text] [Related]
9. Mammalian DNA topoisomerase I activity and poisoning by camptothecin are inhibited by simian virus 40 large T antigen.
Pommier Y; Kohlhagen G; Wu C; Simmons DT
Biochemistry; 1998 Mar; 37(11):3818-23. PubMed ID: 9521701
[TBL] [Abstract][Full Text] [Related]
10. Structures of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex.
Staker BL; Feese MD; Cushman M; Pommier Y; Zembower D; Stewart L; Burgin AB
J Med Chem; 2005 Apr; 48(7):2336-45. PubMed ID: 15801827
[TBL] [Abstract][Full Text] [Related]
11. Effect of E-ring modifications in camptothecin on topoisomerase I inhibition: a quantum mechanics treatment.
Xiao X; Cushman M
J Org Chem; 2005 Nov; 70(23):9584-7. PubMed ID: 16268636
[TBL] [Abstract][Full Text] [Related]
12. Novel indenoisoquinolines NSC 725776 and NSC 724998 produce persistent topoisomerase I cleavage complexes and overcome multidrug resistance.
Antony S; Agama KK; Miao ZH; Takagi K; Wright MH; Robles AI; Varticovski L; Nagarajan M; Morrell A; Cushman M; Pommier Y
Cancer Res; 2007 Nov; 67(21):10397-405. PubMed ID: 17974983
[TBL] [Abstract][Full Text] [Related]
13. Use of camptothecin-resistant mammalian cell lines to evaluate the role of topoisomerase I in the antiproliferative activity of the indolocarbazole, NB-506, and its topoisomerase I binding site.
Urasaki Y; Laco G; Takebayashi Y; Bailly C; Kohlhagen G; Pommier Y
Cancer Res; 2001 Jan; 61(2):504-8. PubMed ID: 11212241
[TBL] [Abstract][Full Text] [Related]
14. Bisindenoisoquinoline bis-1,3-{(5,6-dihydro-5,11-diketo-11H-indeno[1,2-c]isoquinoline)-6-propylamino}propane bis(trifluoroacetate) (NSC 727357), a DNA intercalator and topoisomerase inhibitor with antitumor activity.
Antony S; Agama KK; Miao ZH; Hollingshead M; Holbeck SL; Wright MH; Varticovski L; Nagarajan M; Morrell A; Cushman M; Pommier Y
Mol Pharmacol; 2006 Sep; 70(3):1109-20. PubMed ID: 16798938
[TBL] [Abstract][Full Text] [Related]
15. Eukaryotic DNA topoisomerases mediated DNA cleavage induced by a new inhibitor: NSC 665517.
Gupta M; Abdel-Megeed M; Hoki Y; Kohlhagen G; Paull K; Pommier Y
Mol Pharmacol; 1995 Oct; 48(4):658-65. PubMed ID: 7476891
[TBL] [Abstract][Full Text] [Related]
16. Synthesis of cytotoxic indenoisoquinoline topoisomerase I poisons.
Strumberg D; Pommier Y; Paull K; Jayaraman M; Nagafuji P; Cushman M
J Med Chem; 1999 Feb; 42(3):446-57. PubMed ID: 9986716
[TBL] [Abstract][Full Text] [Related]
17. Modulation in kinetics of lactone ring hydrolysis of camptothecins upon interaction with topoisomerase I cleavage sites on DNA.
Chourpa I; Riou JF; Millot JM; Pommier Y; Manfait M
Biochemistry; 1998 May; 37(20):7284-91. PubMed ID: 9585542
[TBL] [Abstract][Full Text] [Related]
18. Activation of camptothecin derivatives by conjugation to triple helix-forming oligonucleotides.
Arimondo PB; Laco GS; Thomas CJ; Halby L; Pez D; Schmitt P; Boutorine A; Garestier T; Pommier Y; Hecht SM; Sun JS; Bailly C
Biochemistry; 2005 Mar; 44(11):4171-80. PubMed ID: 15766244
[TBL] [Abstract][Full Text] [Related]
19. Synthesis of nitrated indenoisoquinolines as topoisomerase I inhibitors.
Morrell A; Antony S; Kohlhagen G; Pommier Y; Cushman M
Bioorg Med Chem Lett; 2004 Jul; 14(14):3659-63. PubMed ID: 15203138
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of indenoisoquinoline topoisomerase I inhibitors using a hollow fiber assay.
Morrell A; Jayaraman M; Nagarajan M; Fox BM; Meckley MR; Ioanoviciu A; Pommier Y; Antony S; Hollingshead M; Cushman M
Bioorg Med Chem Lett; 2006 Aug; 16(16):4395-9. PubMed ID: 16750365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]